NCT02271139No Longer Available不适用
An Open Label, Multicenter, Single-Arm, Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 44
研究概览
简要总结
This is an open-label, multicenter, single-arm, expanded access study designed to provide alectinib to participants with ALK-rearranged NSCLC after disease progression on or intolerance to prior ALK tyrosine kinase inhibitor (TKI) therapy. Participants will receive alectinib until disease progression, unacceptable toxicity, withdrawal of consent, patient or physician decision to discontinue treatment, death, alectinib becomes commercially available in the United States following approval of alectinib by the FDA, or the Sponsor decides to close the trial, whichever occurs first (approximately 15 months).
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants with locally advanced (American Joint Committee on Cancer [AJCC] Stage IIIB) not amenable to curative therapy or metastatic (AJCC Stage IV) NSCLC
- •Life expectancy of at least 12 weeks
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-3
- •Histologically confirmed NSCLC
- •Documented ALK rearrangement as assessed by approved fluorescence in situ hybridization (FISH) test, using the Vysis ALK Break Apart FISH Probe Kit or the Ventana immunohistochemistry (IHC) test
- •After disease progression on or intolerance to prior ALK TKI therapy: 1) participants need to have a minimum washout period of at least 5 half-lives between the last dose of ALK TKI therapy or other targeted therapies and the first dose of study treatment; 2) participants must have recovered from treatment toxicities to less than or equal to (</=) Grade 1 or to their pretreatment levels (for participants who have developed interstitial lung disease [ILD], they must have fully recovered); 3) participants can either be chemotherapy-naïve or have received at least one line of platinum-based chemotherapy for locally advanced or metastatic disease
- •Recovery from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment
- •Adequate hematological and renal function
- •Agreement to use highly effective methods of contraception per protocol definitions
排除标准
- •Prior therapy with alectinib
- •Participants with symptomatic central nervous system (CNS) metastases who are neurologically unstable or require increasing doses of steroids within 1 week prior to Day 1 to manage CNS symptoms
- •Administration of strong/potent cytochrome P450 3A (CYP3A) inhibitors or inducers, or agents with potential QT prolonging effects within 14 days prior to first administration of study drug
- •Participants with liver disease
- •Any clinically significant concomitant disease or condition that could interfere with the conduct of the study
- •Active or uncontrolled infectious diseases requiring treatment
- •History of organ transplant
- •Participants with baseline QTc > 470 milliseconds (ms) or participants with symptomatic bradycardia
- •Pregnant or lactating, or intending to become pregnant during the study
- •History of hypersensitivity to any of the additives in alectinib formulation
- •Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the participants before trial entry
- •Serious, uncontrolled infections or current known infection with human immunodeficiency virus (HIV)
研究者
研究点 (44)
Loading locations...
相似试验
No Longer Available
不适用
Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c MelanomaUnresected Stage IIIB to IVM1c MelanomaNCT02297529Amgen
进行中（未招募）
4 期
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal MetastasesCarcinoma, Non-Small-Cell LungBrain MetastasesLeptomeningeal MetastasisNCT06282874Guangdong Association of Clinical Trials41
尚未招募
早期 1 期
An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis (ALS)NCT06645197Peking University Third Hospital7
已完成
4 期
To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian CancerBRCA or HRR+ Mutated Ovarian Cancer PatientsNCT02476968AstraZeneca181
终止
早期 1 期
A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant TumorsAdvanced Solid TumorRelapsed/Refractory LymphomaNCT05271279Beijing Boren Hospital2